Form 8-K - Current report:
SEC Accession No. 0001641172-25-001682
Filing Date
2025-03-31
Accepted
2025-03-31 16:01:25
Documents
14
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 35144
2 ex99-1.htm EX-99.1 86661
  Complete submission text file 0001641172-25-001682.txt   313280

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE dare-20250331.xsd EX-101.SCH 3033
4 XBRL LABEL FILE dare-20250331_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE dare-20250331_pre.xml EX-101.PRE 22371
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3661
Mailing Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122
Business Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122 858-926-7655
Dare Bioscience, Inc. (Filer) CIK: 0001401914 (see all company filings)

EIN.: 204139823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36395 | Film No.: 25793009
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)